title: Maternal and fetal atrial natriuretic peptide levels, maternal plasma renin activity, angiotensin II, prostacyclin and thromboxane A2 levels in normal and preeclamptic pregnancies.
abstract: To clarify the possible role of elevated atrial natriuretic peptide (ANP) in the pathophysiology of preeclampsia, we measured ANP, renin activity (PRA), angiotensin II (Ang II), TXB2 (a stable metabolite of TXA2) and 6-keto-PGF1 alpha (a stable end product of PGI2) concentrations in the plasma of 19 normal pregnant women and 35 severe preeclamptic patients at term. Plasma ANP levels in the preeclamptic patients (n = 35, 71.5 +/- 3.8 pg/ml, mean +/- S.E.) and also umbilical plasma ANP (n = 35, 83.0 +/- 4.2 pg/ml) were significantly (p less than 0.01) higher than those of normal pregnant women plasma (n = 19, 58.7 +/- 3.7 pg/ml) and umbilical plasma (n = 19, 47.6 +/- 4.7 pg/ml). There was a significant (p less than 0.01) positive correlation between maternal ANP levels and fetal ANP levels (n = 54, r = 0.44). Plasma PRA and 6-keto-PGF1 alpha levels in preeclampsia were significantly (p less than 0.05) lower than those of normal pregnancy. The ratio of 6-keto-PGF1 alpha/TXB2 in preeclampsia was significantly (p less than 0.01) lower than that of normal pregnancy as we reported previously. There was no significant correlation between plasma ANP level and plasma PRA, Ang II, plasma TXB2 and 6-keto-PGF1 alpha concentrations. Moreover there was no significant correlation between plasma ANP level and the severity of preeclampsia. These data suggest the possibility of a transplacental crossing of ANP secreted by feto-placental unit, which might be, at least in part, responsible for the high ANP levels observed in preeclampsia. The ANP in preeclampsia is not related directly to hypertension, but it may play a substantial role in the regulation or normalization of blood volume and vascular reactivity.
authors.affiliation: Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai.
authors.forename: N
authors.initials: N
authors.lastname: Furuhashi
authors.forename: M
authors.initials: M
authors.lastname: Tsujiei
authors.forename: H
authors.initials: H
authors.lastname: Kimura
authors.forename: A
authors.initials: A
authors.lastname: Yajima
authors.forename: H
authors.initials: H
authors.lastname: Nagae
authors.forename: C
authors.initials: C
authors.lastname: Kimura
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000328:Adult; D000804:Angiotensin II / Q000097:blood*; D009320:Atrial Natriuretic Factor / Q000097:blood / Q000378:metabolism*; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D011464:Epoprostenol / Q000097:blood*; D005260:Female; D005333:Fetus / Q000378:metabolism*; D006801:Humans; D011225:Pre-Eclampsia / Q000097:blood / Q000378:metabolism*; D011247:Pregnancy; D011863:Radioimmunoassay; D012083:Renin / Q000097:blood*; D013928:Thromboxane A2 / Q000097:blood*
chemical_list: D000804:Angiotensin II; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; D009320:Atrial Natriuretic Factor; D011464:Epoprostenol; D012083:Renin